

Under the Paperwork Reduction Act of 1995, no Persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/582,124; Conf. No. 1776
(Use as many sheets as necessary)		Filing Date	May 10, 2007
Sheet	1	First Named Inventor	Linda Greensmith
	of 1	Art Unit	1628
		Examiner Name	Christopher R. Stone
		Attorney Docket Number	CytRx/012

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication or Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T ⁶

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		BENN et al., "Putting the heat on ALS," <i>Nature Medicine</i> , 10(4):345-347 (2004).			
		CSARDI et al., "Pharmacokinetic study on a new antiischaemic agent (BRLP-42)", <i>Acta Physiologica Hungarica</i> , 82(4):321-326 (1994).			
		EUROPEAN EXTENDED SEARCH REPORT, August 28, 2009, European Application 08157425.3.			
		INTERNATIONAL SEARCH REPORT, February 28, 2005, PCT Publication WO 2005/041965.			
		KIERAN et al., "Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice," <i>Nature Medicine</i> , 10(4):402-405 (2004).			
		KURTHY et al., "Effect of BRX-220 against peripheral neuropathy and insulin resistance in Diabetic rat models," <i>Annals of the New York Academy of Sciences</i> , 967:482-489 (2002).			
		LOVE, "Arimoclomol delays progression in ALS mouse model," <i>Lancet Neurology</i> , 3(5):264 (2004).			
		TOTH et al., "Effect of bimoclomol 1 (N-(2-hydroxy-3-(1-piperidinyl) propoxy)-3-pyridine-carboximidoyl-chloride) on iminodipropionitrile-induced central effects," <i>Neurochemistry International</i> , 33(6):513-518 (1998).			
		VISY et al., "Enantioselective Plasma Protein Binding of Bimoclomol," <i>Chirality</i> , 14:638-642 (2002).			

Examiner Signature	/Christopher Stone/	Date Considered	10/23/2009
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.